Objectives: Development of single dose antibiotic treatments for chancroid has been followed by drug-resistant Haemophilus ducreyi in endemic areas. We examined the activity and interactions of antimicrobial agents and combinations against H. ducreyi.
Introduction
The Gram-negative bacterium Haemophilus ducreyi is the causative agent of the sexually transmitted disease (STD) chancroid. 1 Chancroid is a common form of genital ulcer disease in the developing world, and also occurs in marginalized groups with limited access to healthcare services. Chancroid has received considerable interest in recent years because it has epidemiological synergy with HIV infection, and each may facilitate transmission of the other. [2] [3] [4] Chancroid can be treated with relative ease, and even established outbreaks can be controlled. [5] [6] [7] [8] In addition to HIV infection, chancroid outbreaks are associated with prostitution 9,10 and crack-cocaine use. 11, 12 Studies of improved STD treatment in endemic regions demonstrate a 40% reduction in HIV transmission in Mwanza, Tanzania, 13 and no effect on HIV incidence in Rakai, Uganda, where there was a low incidence of treatable STD and a high prevalence of HIV. 14 In a 1988 survey of H. ducreyi strains isolated in South Africa, most were found to be resistant to penicillin, tetracycline, sulfamethoxazole, and trimethoprim. 15 H. ducreyi, once susceptible to sulphonamides, penicillins, tetracyclines, and trimethoprim, has developed plasmid or chromosomally encoded resistance to Tel: +1-613-737-8923; Fax: +1-613-737-8925; E-mail: bcameron@ohri.ca each. [16] [17] [18] Discrete susceptibility profiles in different regions are also reported, often reflecting differential drug use. 19 Several single-dose regimens have been shown to be effective for the treatment of chancroid, including ceftriaxone, ciprofloxacin, azithromycin, and sulfamethoxazole/trimethoprim. 20 Despite documented H. ducreyi resistance to it, 21 streptomycin is still an alternative treatment. 22 With the growing prevalence of HIV co-infection, however, single-dose therapies of ceftriaxone, azithromycin, fleroxacin, ciprofloxacin, erythromycin and trimethoprim/sulfamethoxazole are associated with greater than 20% chancroid treatment failure rates. [23] [24] [25] [26] Also, there is regional variation of chancroid response to azithromycin, 27 and chancroid treatment failure attributable to herpes simplex virus (HSV) co-infection 28 or drug resistance. As H. ducreyi is adept at acquiring new gene products through horizontal mechanisms, both in its genome, e.g. cytolethal distending toxin, 29 and on stably transmitted plasmids, 18, 30 it may acquire resistance genes through horizontal transmission as well as through de novo mutation. Although clinical evidence of this complex problem is limited to simple observational study methods, theoretical and mathematical models show that effective combination therapy can limit the emergence of antibiotic resistance at the population level. 31 Efficacious singledose treatment regimens may improve compliance-related effectiveness of treatment programmes and reduce the emergence of antibiotic resistance, 20 and are desirable as chancroid therapy. Combination antibiotic therapy has improved therapeutic efficacy in other bacterial infectious conditions and in the immunosuppressed patient. 32 We aimed to demonstrate the principle, and propose that antibiotic combinations may be developed as single-dose, effective and sustained treatment of chancroid, suitable for treatmentbased chancroid control programmes. We screened antibiotics of unrelated class and each of their two-antibiotic combinations for in vitro antimicrobial activity against susceptible H. ducreyi strains, and then evaluated the most promising antibiotic combination for in vivo treatment efficacy in the temperature-dependent rabbit model of chancroid. and high humidity, while broth cultures were incubated for 12 h at 33 C in an environmental shaker at 175 rpm. Reference strains of E. coli and S. aureus were grown in CA or Mueller-Hinton broth supplemented with 1% IsoVitaleX. Plates were incubated for 24 h at 37 C in 5% CO 2 and broth cultures were incubated for 2 h at 37 C in an environmental shaker (Lab-line, Melrose Park, IL, USA).
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Materials and methods
Bacterial strains and culture conditions
Animals
Animals were treated in accordance with the Animal Care and Veterinary Services procedures. The Animal Care Committee at the University of Ottawa approved all experiments. Male New Zealand White Rabbits (2.5-3 kg) (Charles River Laboratories, Montreal, PQ, Canada) were housed in an 11.7 m 2 room at the Animal Care Facility at the University of Ottawa Health Science Centre. The temperature in the room was maintained at 14 C with a Thermo Air plus air conditioning unit. The backs of the rabbits were shaved prior to infection and when necessary. All rabbits were kept under identical conditions for the duration of the experiments.
Antibiotics
Ceftriaxone (Sigma Chemical Co., St Louis, MO, USA), streptomycin (Sigma), azithromycin (Pfizer, Pointe-Claire-Dorval, PQ, Canada), and rifabutin (Farmitaliz Carlo Erba, Nerviano, Italy) were used in the experiments.
In vitro antimicrobial susceptibility testing
MIC and fractional inhibitory concentration index (FICI) determinations were measured by agar dilution on CA plates supplemented with 1% gonococcal supplement B (Difco Laboratories, Detroit, MI, USA). Plates were incubated for 48 h at 33 C in 5% CO 2 in a humid chamber. All strains were tested for their susceptibility to ceftriaxone, streptomycin, azithromycin and rifabutin. All stock solutions were prepared in double distilled water. Azithromycin and rifabutin were initially dissolved in methanol (<2% of the final volume) because of their lack of solubility in water.
MIC determination. MIC was determined using the agar dilution method of the NCCLS with modifications. 36, 37 Ceftriaxone, streptomycin, azithromycin and rifabutin were diluted in water and incorporated into CA at 50 C to yield the appropriate 2-fold dilution series. Final concentration ranges tested were 0.001-8 mg/L for ceftriaxone, 0.063-512 mg/L for streptomycin, 0.00005-4 mg/L for azithromycin, and 0.002-2 mg/L for rifabutin. The agar was poured into 100 · 15 mm Petri dishes (Fisher Scientific, Nepean, ON, Canada), to a depth of 3-4 mm. Plates were used the same day or were stored at 4 C for use the following day. H. ducreyi strains were grown on CA plates for 48 h, and inoculated on new plates that were incubated for 24 h. The growth was suspended in Mueller-Hinton broth with 1% IsoVitaleX and allowed to sediment for at least 15 min at room temperature. The optical density of each supernatant was adjusted to that of a 0.5 McFarland barium sulphate standard. A few colonies of the reference strains were selected from plates grown for 24 h at 37 C and were inoculated into 4 mL of Mueller-Hinton broth supplemented with 1% IsoVitaleX. This suspension was incubated at 37 C for 2 h. All suspensions were diluted 1:10 and 2 mL (10 4 cfu) was inoculated onto the plates with a pipette. MIC was defined as the lowest concentration of an antibiotic that completely inhibits growth (disregarding a single colony) after 48 h at 33 C in 5% CO 2 and high humidity. Assays were performed in duplicate. FICI determination. FICI for H. ducreyi strains 35000, RO 40 and RO 34 exposed to varying concentrations of all two-drug combinations of ceftriaxone, azithromycin, rifabutin and streptomycin were determined Combination antimicrobials and Haemophilus ducreyi using the chequerboard agar dilution method. 38 Plates and inocula were prepared and incubated for MIC determination as described above. The assays were performed in duplicate in three separate experiments.
In vivo antimicrobial susceptibility testing
Experimental induction of infection. Experimental infections were induced and assayed as previously described. 35, 39 Briefly, brothgrown H. ducreyi strains 35000 and RO 40 were harvested at the late mid-log phase, defined by time of incubation, i.e. 4-6 h, by centrifugation at 3000 g for 10 min. Pellets were washed once with PBS (Gibco BRL), pH 7.2, and resuspended in Mueller-Hinton broth. Serial 10-fold dilutions of H. ducreyi broth, from 10 7 to 10 3 cfu/mL were prepared, and injected intraepithelially in triplicate in 100 mL doses, for a total of 15 injections, into the shaved backs of the animals, to give five final inocula doses of 10 6 to 10 2 cfu. The actual inoculum size was determined by colony count after diluting and plating 100 mL on CA plates and incubating at 33 C with 5% CO 2 and high humidity.
Determination of lesion severity. Two of three lesions were measured and scored daily, for a period of 21 days for each inoculum size on each rabbit (0 = nil, 1 = erythema, 2 = induration, 3 = suppuration, 4 = ulceration). The third lesion was cultured for the presence of H. ducreyi by lateral injection of 0.1 mL of PBS at pH 7.2, manipulation, and aspiration. The aspirate was cultured on CA plates for 48 h at 33 C and examined for evidence of typical H. ducreyi colony morphology by the push test, Gram stain, and microscopic examination. Culture was discontinued after four consecutive days of negative culture results.
Determination of sub-therapeutic antibiotic dose. Preliminary experiments using single-dose, single-drug treatment with 0.05-5 mg/kg of ceftriaxone and 2.5-15 mg/kg of streptomycin established that 0.05 mg/kg of ceftriaxone and 10 mg/kg of streptomycin were the highest doses which had no effect on lesion healing relative to controls without antibiotic treatment in the temperature-dependent rabbit model of chancroid. Efficacy of antimicrobial treatment. H. ducreyi 35000 was used to examine in vivo antibiotic efficacy. Inocula of 10 4 cfu were injected into the shaved backs of the rabbits in a 15-location grid pattern. Rabbits were treated with antibiotics upon ulceration of the lesions on day 4 post-infection. Single sub-therapeutic doses of 0.05 mg/kg of ceftriaxone (n = 4), 10 mg/kg of streptomycin (n = 4), and a combination of both antibiotics (n = 5) were administered intramuscularly. Control rabbits (n = 3) received no treatment. Odd numbered lesions (8/rabbit) were measured and scored daily for 17 days posttreatment. Even numbered lesions were cultured until negative for four consecutive days.
Statistical analysis
Analysis of variance (ANOVA) was used to compare the FICI between strains and the Student-Newman-Keuls method was used where ANOVA showed a significant difference. The Kruskal-Wallis ANOVA on ranks was used in instances where normality failed. Comparative analysis of in vivo efficacy of treatment on ulcerative lesions was done on data from treatment day 0 (on the fourth day from infection) to day 17. Serial lesion sizes were expressed as a percentage of pre-treatment lesion size, so that all lesions were 100% on day 0. For each rabbit, for each of 17 treatment days, the median lesion size percentage and median lesion score were calculated from eight of the 15 inoculation sites. The mean time in days for a 50% decrease in median lesion size, and the mean time in days to reach a median score of 2 were compared between groups. For each rabbit, the median duration of lesion culture positivity was calculated. Mean time in days to culture positivity was compared between groups. For each rabbit, the median inoculum size was calculated, and the means of the groups were compared. Comparisons were carried out by ANOVA, followed by the Tukey post-hoc test where appropriate. Statistical analysis was performed using SigmaStat software (SPSS Science, Chicago, IL, USA).
Results
In vitro antimicrobial susceptibility testing MIC determination. MICs for H. ducreyi strains 35000, RO 40 and RO 34 show that they were susceptible to the four antibiotics tested, and the MICs for the reference strains E. coli ATCC 25922 and S. aureus ATCC 29213 were all within one dilution of the accepted ranges (Table 1) .
FICI determination. FICIs for each two-antibiotic combination tested in vitro against each H. ducreyi strain are shown in Table 2 . All three H. ducreyi strains had an FICI of 0.63 for the combination of ceftriaxone and streptomycin. FICI was determined to be 1.5 for ceftriaxone + azithromycin and streptomycin + azithromycin for all three strains tested, indicating that these antibiotics do not interact in either a synergic or antagonistic manner. Drug combinations including rifabutin were much more variable in their effects in all strains than combinations without this drug.
In vivo antimicrobial susceptibility testing
Experimental induction of infection. The lowest inoculum size of H. ducreyi strain 35000 to consistently produce ulcerative lesions in this model is 10 4 cfu. 39, 40 Rabbits were inoculated with 10 4 cfu of H. ducreyi strain 35000 (100 mL of 10 5 cfu/mL) in a pattern of 5 rows of 3 columns. The actual input inoculum size was measured by limiting dilution of residual inocula immediately after injection (Table 3 ). There was no statistically significant difference in the inoculum size for the different treatments (P = 0.4, ANOVA).
Determination of sub-therapeutic antibiotic dose. The combination of ceftriaxone + streptomycin had the lowest FICI in vitro, so this combination was examined for antimicrobial activity and in vivo efficacy in the temperature-dependent rabbit model of chancroid. Sub-therapeutic concentrations of ceftriaxone and streptomycin, defined as the highest concentration of the individual drug without reduction in days of culture positivity, or the rate of resolution as assessed by lesion score and diameter, were determined. Streptomycin was used in doses of 2.5, 5, 10 and 15 mg/kg. Only the highest concentration resulted in accelerated healing of ulcers, thus the 10 mg/kg dose was determined to be the highest sub-therapeutic dose (data not shown), and used in subsequent experiments. Similarly, ceftriaxone was tested at concentrations of 0.05, 0.1 and 5.0 mg/kg, and 0.05 mg/kg was the highest dose not significantly different from the control (data not shown), and was used as the sub-therapeutic dose in subsequent experiments.
Efficacy of antimicrobial treatment. To evaluate interaction, once the lesions had ulcerated on day 4 after infection, rabbits were either not treated (n = 3) or treated with intramuscular injections of 0.05 mg/kg of ceftriaxone (n = 4), 10 mg/kg of streptomycin (n = 4), or both (n = 5). Results are shown in Figure 1 and Table 3 . Rabbits receiving a single 0.05 mg/kg dose of ceftriaxone or a single 10 mg/kg dose of streptomycin did not differ significantly from the untreated animals with respect to mean (SD) duration of culture positivity in days [7.0 (2.7) and 7.5 (2.1), versus 7.3 (1.1), P > 0.8]; mean (SD) time in days to a 50% decrease from pretreatment lesion size [8.2 (1.7) and 8.5 (0.6) versus 9.7 (1.5), P > 0.2]; and mean (SD) time in days to reach a lesion score of 2 from a pre-treatment score of 4 [9.7 (2.7) and 9.4 (1.7) versus 11.7 (2.3), P > 0.2]. However, simultaneous treatment with the same concentrations of both antibiotics resulted in abatement of disease. Table 3 shows that the mean (SD) duration of culture positivity was 2.6 (1.7) days in the treated animals versus 7.3 (1.1) days in the untreated controls (P < 0.001), mean time to 50% reduction in lesion size was reduced from 9.7 (1.5) days to 5.8 (0.8) days (P < 0.005), and the mean time to reduction in lesion score from 4 to 2 was reduced from 11.7 (2.3) days in control animals to 6.6 (1.7) days (P < 0.05) with treatment.
Discussion
Our findings indicate an in vivo synergic interaction between ceftriaxone and streptomycin. As there is no generally accepted definition of in vivo synergy, we used the definition of Cleeland and Squires. 41 In vitro, each virulent strain of H. ducreyi was Table 2 . FICI for all two-drug combinations of antimicrobial agents against Haemophilus ducreyi The highest dose which had no effect alone on lesion healing compared with controls. b The last day of culture positivity, after which at least two sequential cultures were negative. individually susceptible to streptomycin, ceftriaxone, azithromycin and rifabutin, and each two-antibiotic combination. The combination of streptomycin and ceftriaxone consistently obtained the lowest FICI at 0.63. An FICI of 0.5 or lower is interpreted as indicating synergy, above 4.0 antagonism, and no interaction is assumed between these values, 42 although an FICI of 1.0 may be interpreted as indicating additive activity. 38 Although not strictly indicative of an in vitro synergic interaction, this FICI of 0.63 was suggestive of an additive or potentially synergic interaction that warranted further in vivo investigation. In the temperaturedependent rabbit model of chancroid, treatment with combined sub-therapeutic doses of streptomycin and ceftriaxone, the highest doses that had no effect alone on healing of lesions, was associated with statistically significant reduction in time of culture positivity, size, and resolution of lesions. This is the first time positive antibiotic interactions against H. ducreyi have been reported. This in vivo synergy is not unexpected, as there is evidence of broad synergic interactions with combination b-lactam and aminoglycoside antibiotics, both in vitro 43, 44 and in vivo. 45, 46 The theoretical basis for this interaction is the increased uptake of the aminoglycoside in the presence of the cell-wall-active b-lactam. 47 Streptomycin and ceftriaxone have been used separately in the treatment of chancroid and are affordable. Ceftriaxone is well tolerated and safe, with occasional allergic reactions. Streptomycin is associated with ototoxicity and nephrotoxicity when used at high doses for extended periods of time. 48, 49 Although commonly used to determine in vitro antibiotic interactions, the chequerboard method has several limitations, such as reliance on a single time point, assumption of a linear doseresponse for all antimicrobials, and an all-or-nothing read out, 38 and has been described as inherently unstable as a predictor of synergy because of its reliance on 2-fold dilutions. 50 Time-kill methods can address some of the shortcomings of the chequerboard method of susceptibility testing. 51 It is recognized in the field of antibiotic testing that special measures are needed in dealing with fastidious organisms, 52 but no standardized culture procedure exists for this fastidious organism, and there was no precedent for the evaluation of antimicrobial activity on H. ducreyi in liquid media. We opted for the chequerboard agar dilution technique, which has been used with H. ducreyi in MIC determination in the past. 36, 37 We chose streptomycin, an aminoglycoside, ceftriaxone, a cephalosporin, and azithromycin, an azalide, as they have all been used to treat chancroid. We chose rifabutin, a semi-synthetic ansamycin, as it may be appropriate for single-dose therapy because of high in vitro susceptibility of H. ducreyi, high tissue binding, and long elimination half-life. By evaluating subtherapeutic doses of antibiotics, we were able to properly evaluate synergic, indifferent, or additive effects, and not antagonistic effects, of the selected antibiotic combinations. We did not test potentially additive or synergic rifabutin antibiotic combinations in vivo, as they lacked consistent in vitro activity. As with other organisms and antibiotics, however, in vitro activity may not always reflect in vivo efficacy, especially when the chequerboard agar dilution method is used to determine FICI, 41 and other twodrug combinations including fluoroquinolones may well deserve consideration.
It may be reasonable to predict similar interactions of other aminoglycosides and cephalosporins against H. ducreyi, however, several authors have cautioned that interaction between antibiotics is dependent upon the antibiotics used, the organism being tested, and, to some extent, the medium or the host. 53, 54 This study demonstrates the in vivo therapeutic synergy of streptomycin and ceftriaxone against H. ducreyi in an animal model of infection and disease. Antibiotic combinations need clinical evaluation as chancroid treatment, especially where consistently efficacious treatment is lacking or improved single-dose observed therapy is desirable. 
